A European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Dyslipidemia With or Without Other Comorbidities
Latest Information Update: 04 Apr 2022
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms ETERNAL
- Sponsors Sanofi
- 04 Apr 2022 This trial has been completed in Netherlands (End Date: 30 Jan 2009), according to European Clinical Trials Database record.
- 19 Jan 2022 This trial has been completed in Greece (End Date: 30 Jan 2009), according to European Clinical Trials Database record.
- 07 Jul 2009 Actual patient number (645) added as reported by ClinicalTrials.gov.